Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: A randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

Blood

Volumn 120, Issue 24, 2012, Pages 4706-4711

  Ossenkoppele, Gert J ^a   Stussi, Georg ^b   Maertens, Johan ^c   Van Montfort, Kees ^d   Biemond, Bart J ^e   Breems, Dimitri ^f   Ferrant, August ^g   Graux, Carlos ^h   De Greef, Georgine E ^d   Halkes, C J M ⁱ   Hoogendoorn, Mels ^j   Hollestein, Rene M ^d   Jongen Lavrencic, Mojca ^d   Levin, Mark D ^k   Van De Loosdrecht, Arjan A ^a   Van Marwijk Kooij, Marinus ^l   Van Norden, Yvette ^d   Pabst, Thomas ^m   Schouten, Harry C ⁿ   Vellenga, Edo ^o   Verhoef, Gregor E G ^c   De Weerdt, Okke ^p   Wijermans, Pierre ^g   Passweg, Jakob R ^q   Loẅenberg, Bob ^d   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f Hospital Network Antwerp (ZNA) Middelheim   (Belgium)

^g Leiden University Medical Center ^*  (Netherlands)

^h MT Godinne   (Belgium)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j MEDICAL CENTER LEEUWARDEN   (Netherlands)

^k ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^l Sophia Hospital   (Netherlands)

^m UNIVERSITY OF BERN   (Switzerland)

ⁿ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^o UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^p ST ANTONIUS HOSPITAL   (Netherlands)

^q UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADULT; AGED; ARTICLE; BLEEDING; CANCER RESEARCH; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG WITHDRAWAL; ELDERLY CARE; EVENT FREE SURVIVAL; FEMALE; HUMAN; HYPOPLASIA; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84870740661     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-420596     Document Type: Article

References (19)

1. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
2. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. N Engl J Med. 2009;361(13):1235-1248.
3. Ziogas DC, Voulgarelis M, Zintzaras E. A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clin Ther. 2011;33(3):254-279.
4. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55:15-35.
5. de Bont ES, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol. 2001;113(2):296-304. (Pubitemid 32523131)
6. Padró T, Ruiz S, Bieker H, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95(8):2637- 2644. (Pubitemid 30210544)
7. Shih TT-F, Tien H-F, Liu C-Y, et al. Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukaemia. Leukemia. 2006;20(2):357-362. (Pubitemid 43148680)
8. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94(11):3717-3721.
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400. (Pubitemid 38618122)
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342. (Pubitemid 38702844)
11. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. TARGET Study Group. N Engl J Med. 2007;356(2):125-134. (Pubitemid 46089673)
12. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
13. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. J. Clin Cancer Res. 2004;10(11):3577-3585. (Pubitemid 38697590)
14. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791- 4797.
15. Weidenaar AC, ter Elst A, Koopmans-Klein G, et al. High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow. Cell Oncol (Dordr). 2011;34(4):289-296.
16. Ocaña A, Amir E, Vera F, et al. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol. 2011;29(3):254-256.
17. Estey E. Clinical trials in AML of the elderly: should we change our methodology? Leukemia. 2004;18(11):1772-1774. (Pubitemid 39530005)
18. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood. 2003;102(2):442-448. (Pubitemid 36841959)
19. Hills RK, Burnett AK. Applicability of a "pick a winner"trial design to acute myeloid leukemia. Blood. 2011;118(9):2389-2394.